 Mathew Angelos
Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoiesis | 4 | 2024 | 195 | 1.490 |
Why?
| | Pluripotent Stem Cells | 3 | 2018 | 81 | 1.110 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2018 | 61 | 1.020 |
Why?
| | Hematologic Neoplasms | 2 | 2026 | 169 | 0.870 |
Why?
| | Immunotherapy, Adoptive | 6 | 2026 | 356 | 0.850 |
Why?
| | Cell Differentiation | 4 | 2024 | 2054 | 0.720 |
Why?
| | Hematopoietic Stem Cells | 4 | 2024 | 435 | 0.660 |
Why?
| | Neoplasms | 6 | 2025 | 2946 | 0.570 |
Why?
| | T-Lymphocytes | 4 | 2026 | 2017 | 0.470 |
Why?
| | Regenerative Medicine | 1 | 2015 | 49 | 0.450 |
Why?
| | Immunotherapy | 3 | 2025 | 672 | 0.440 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 277 | 0.370 |
Why?
| | Fetal Blood | 2 | 2010 | 327 | 0.340 |
Why?
| | Cell Proliferation | 2 | 2018 | 2529 | 0.330 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 679 | 0.300 |
Why?
| | Stress, Mechanical | 1 | 2010 | 494 | 0.280 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1339 | 0.260 |
Why?
| | Endothelial Cells | 2 | 2010 | 886 | 0.250 |
Why?
| | Embryonic Stem Cells | 2 | 2017 | 124 | 0.240 |
Why?
| | CD2 Antigens | 1 | 2026 | 7 | 0.240 |
Why?
| | Stem Cells | 1 | 2010 | 630 | 0.230 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 748 | 0.230 |
Why?
| | Medical Oncology | 2 | 2025 | 344 | 0.220 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 55 | 0.220 |
Why?
| | CD5 Antigens | 1 | 2024 | 10 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2024 | 5 | 0.210 |
Why?
| | Hemangiosarcoma | 1 | 2024 | 27 | 0.200 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2025 | 79 | 0.200 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 293 | 0.200 |
Why?
| | Pyridones | 1 | 2025 | 210 | 0.190 |
Why?
| | Receptors, Immunologic | 1 | 2024 | 210 | 0.190 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 124 | 0.180 |
Why?
| | Sulfonamides | 1 | 2026 | 596 | 0.170 |
Why?
| | Cells, Cultured | 3 | 2017 | 4170 | 0.160 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2026 | 700 | 0.140 |
Why?
| | Humans | 18 | 2026 | 147306 | 0.140 |
Why?
| | Hemangioblasts | 1 | 2017 | 4 | 0.130 |
Why?
| | Antigens, Surface | 1 | 2017 | 155 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2017 | 78 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1530 | 0.120 |
Why?
| | Human Embryonic Stem Cells | 1 | 2015 | 24 | 0.110 |
Why?
| | Animals | 7 | 2026 | 38417 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2015 | 189 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2026 | 2231 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2017 | 1172 | 0.100 |
Why?
| | CRISPR-Cas Systems | 2 | 2026 | 166 | 0.100 |
Why?
| | Genetic Therapy | 1 | 2015 | 317 | 0.100 |
Why?
| | Computational Biology | 1 | 2017 | 677 | 0.090 |
Why?
| | Osteoarthritis, Knee | 1 | 2016 | 284 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3565 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2420 | 0.090 |
Why?
| | Receptors, Vitronectin | 1 | 2010 | 5 | 0.080 |
Why?
| | Cell Size | 1 | 2010 | 94 | 0.080 |
Why?
| | Precision Medicine | 2 | 2025 | 464 | 0.080 |
Why?
| | Diffusion | 1 | 2010 | 120 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1072 | 0.080 |
Why?
| | Solutions | 1 | 2010 | 160 | 0.080 |
Why?
| | Mice | 5 | 2026 | 18493 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 321 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 136 | 0.080 |
Why?
| | Biological Transport | 1 | 2010 | 425 | 0.070 |
Why?
| | Cell Adhesion | 1 | 2010 | 451 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 675 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 121 | 0.070 |
Why?
| | CD58 Antigens | 1 | 2026 | 1 | 0.060 |
Why?
| | United States | 1 | 2023 | 16313 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2025 | 16 | 0.060 |
Why?
| | Tissue Engineering | 1 | 2009 | 439 | 0.060 |
Why?
| | Remission Induction | 1 | 2026 | 310 | 0.050 |
Why?
| | Biphenyl Compounds | 1 | 2025 | 67 | 0.050 |
Why?
| | Azacitidine | 1 | 2026 | 168 | 0.050 |
Why?
| | Morpholines | 1 | 2025 | 130 | 0.050 |
Why?
| | Gossypol | 1 | 2023 | 2 | 0.050 |
Why?
| | Benzamides | 1 | 2025 | 227 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2023 | 138 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 518 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 939 | 0.040 |
Why?
| | Epitopes | 1 | 2023 | 475 | 0.040 |
Why?
| | Antibodies | 1 | 2023 | 398 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 415 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 1205 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2024 | 3153 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1166 | 0.030 |
Why?
| | Female | 4 | 2026 | 80081 | 0.030 |
Why?
| | Viscosupplements | 1 | 2016 | 11 | 0.030 |
Why?
| | Injections, Intra-Articular | 1 | 2016 | 61 | 0.030 |
Why?
| | Braces | 1 | 2016 | 30 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 2001 | 0.030 |
Why?
| | Platelet-Rich Plasma | 1 | 2016 | 41 | 0.030 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2016 | 60 | 0.030 |
Why?
| | Aged | 2 | 2026 | 26516 | 0.030 |
Why?
| | Hyaluronic Acid | 1 | 2016 | 226 | 0.030 |
Why?
| | Middle Aged | 2 | 2026 | 36821 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 487 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 481 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2016 | 383 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2026 | 11947 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 5272 | 0.020 |
Why?
| | Pain | 1 | 2016 | 794 | 0.020 |
Why?
| | Shear Strength | 1 | 2009 | 73 | 0.020 |
Why?
| | Male | 2 | 2026 | 73954 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 375 | 0.020 |
Why?
| | Adult | 1 | 2025 | 41406 | 0.010 |
Why?
|
|
Angelos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|